Illumina to part with Grail, ending battle with regulators
Dive Brief: DNA sequencing company Illumina said Sunday it will divest Grail, the liquid biopsy maker it fought to hang onto after purchasing the business for $8 billion more than two years ago over the objections of U.S. and European regulators. The divestiture will take the form of a capital markets transaction or sale of…
